Skip to main content
Lancet (London, England)
The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action.
Population-wide albuminuria screening: implications for CKD detection and management.
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Generating comparative evidence on new drugs and devices before approval.
Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply.
Statins for people at low risk of cardiovascular disease.
Statins for people at low risk of cardiovascular disease.
Last nail in the coffin for PCI in stable angina?
PlA1/A2 polymorphism of platelet glycoprotein IIIa and risk of cardiovascular disease.
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.
